BioLife Solutions Inc Reports Strong Revenue Growth for 2024
| BLFS Stock | USD 26.19 0.53 1.98% |
Slightly above 62% of BioLife Solutions' investor base is looking to short. The analysis of overall sentiment of trading BioLife Solutions stock suggests that many investors are alarmed at this time. BioLife Solutions' investing sentiment can be driven by a variety of factors including economic data, BioLife Solutions' earnings reports, geopolitical events, and overall market trends.
BioLife |
BioLife Solutions Inc , a prominent developer and supplier of bioproduction products for the cell and gene therapy market, announced its preliminary unaud
Read at gurufocus.com
 |
BioLife Solutions Fundamental Analysis
We analyze BioLife Solutions' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioLife Solutions using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioLife Solutions based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Revenue
Revenue Comparative Analysis
BioLife Solutions is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
BioLife Solutions Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BioLife Solutions stock to make a market-neutral strategy. Peer analysis of BioLife Solutions could also be used in its relative valuation, which is a method of valuing BioLife Solutions by comparing valuation metrics with similar companies.
Peers
BioLife Solutions Related Equities
| ANGO | AngioDynamics | 1.93 | ||||
| ATRC | AtriCure | 0.90 | ||||
| KRMD | Repro Med | 1.02 | ||||
| ATR | AptarGroup | 1.18 | ||||
| TFX | Teleflex Incorporated | 1.37 | ||||
| WST | West Pharmaceutical | 1.39 | ||||
| COO | Cooper Companies, | 1.43 | ||||
| ICUI | ICU Medical | 1.93 | ||||
| ALC | Alcon AG | 1.98 | ||||
| RMD | ResMed | 2.23 | ||||
| AKYA | Akoya Biosciences | 7.04 | ||||
| HAE | Haemonetics | 11.58 |
Additional Tools for BioLife Stock Analysis
When running BioLife Solutions' price analysis, check to measure BioLife Solutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLife Solutions is operating at the current time. Most of BioLife Solutions' value examination focuses on studying past and present price action to predict the probability of BioLife Solutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLife Solutions' price. Additionally, you may evaluate how the addition of BioLife Solutions to your portfolios can decrease your overall portfolio volatility.